Asia Pacific Bangkok Beijing Brisbane Hanoi Ho Chi Minh City Hong Kong Jakarta Kuala Lumpur* Manila* Melbourne Seoul Shanghai Singapore Sydney Taipei Tokyo Yangon Europe, Middle East & Africa Abu Dhabi Almaty Amsterdam Antwerp Bahrain Barcelona Berlin Brussels Budapest Cairo Casablanca Doha Dubai Dusseldorf Frankfurt/Main Geneva Istanbul Jeddah* Johannesburg Kyiv London Luxembourg Madrid Milan Moscow Munich Paris Prague Riyadh* Rome St. Petersburg Stockholm Vienna Warsaw Zurich The Americas Bogota Brasilia** Buenos Aires Caracas Chicago Dallas Guadalajara Houston Juarez Lima Los Angeles Mexico City Miami Monterrey New York Palo Alto Porto Alegre** Rio de Janeiro** San Francisco Santiago Sao Paulo** Tijuana Toronto Washington, DC * Associated Firm ** In cooperation with Trench, Rossi e Watanabe Advogados | | 30 January 2024 The Directors Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Ave SYDNEY NSW 2000 Dear Directors Kazia Therapeutics Limited - Registration Statement on Form F-1 We have acted as Australian legal counsel to Kazia Therapeutics Limited ACN 063 259 754 (Company), a public company limited by shares incorporated under the laws of the Commonwealth of Australia, in connection with its filing with the U.S. Securities and Exchange Commission (Commission) of a registration statement on Form F-1 under the U.S. Securities Act of 1933, as amended (Securities Act) (Registration Statement). The Registration Statement relates to the resale from time to time by the selling shareholders, including its transferees, donees, pledgees or successors-in-interest (Selling Shareholders) identified in the preliminary prospectus contained in the Registration Statement (Preliminary Prospectus) of up to 4,755,556 American Depositary Shares (ADSs), each representing ten fully paid ordinary shares in the capital of the Company (Shares), issued or issuable upon the exercise of warrants comprised of (i) warrants issued in a concurrent private placement in connection with the Company’s registered direct offering in December 2023 (Ordinary Share Warrants), pursuant to the Securities Purchase Agreement, dated as of 30 November 2023, between the Company and the investor named therein (Securities Purchase Agreement), and (ii) warrants issued in a private placement (Placement Agent Warrants), pursuant to an engagement letter dated as of 14 August 2023 (Engagement Letter), between the Company and H.C. Wainwright & Co., LLC. The Ordinary Share Warrants and Placement Agent Warrants are collectively referred to as the Warrants. 1. Documents examined 1.1 For the purposes of this opinion, we have examined and relied on copies of the following documents: (a) the Registration Statement; (b) the Preliminary Prospectus; (c) the Securities Purchase Agreement; (d) the Engagement Letter; and |